Research programme: haemophilia therapeutics - Celtic Pharma/PolyTherics

Drug Profile

Research programme: haemophilia therapeutics - Celtic Pharma/PolyTherics

Alternative Names: Haemophilia therapeutics - Pro Bono Bio; Long-acting blood coagulation factor IX - Pro Bono Bio; Long-acting blood coagulation factor VIIa - Pro Bono Bio; Long-acting blood coagulation factor VIII - Pro Bono Bio; Protein therapeutics - Celtic Pharma/Polytherics; TheraPEG™ Factor IX; TheraPEG™ Factor VIIa; TheraPEG™ Factor VIII

Latest Information Update: 13 Mar 2013

Price : $50

At a glance

  • Originator Celtic Pharma; PolyTherics
  • Developer PolyTherics; Pro Bono Bio
  • Class Blood coagulation factors; Polyethylene glycols
  • Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Haemophilia A; Haemophilia B

Most Recent Events

  • 11 Sep 2012 Pharmacodynamics data from a preclinical study in Haemophilia released by Pro Bono Bio
  • 11 Sep 2012 Preclinical trials in Haemophilia B in United Kingdom (SC)
  • 11 Sep 2012 Preclinical trials in Haemophilia A in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top